-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 T2osO0bICwmBUHPwhtvFXAUE4Sg+90S04vuyF6bbvhh6bXfD/koB3rGfm5MMX9yY
 dM/K9rGCVXFs28SA5juulg==

<SEC-DOCUMENT>0000950123-09-072718.txt : 20091222
<SEC-HEADER>0000950123-09-072718.hdr.sgml : 20091222
<ACCEPTANCE-DATETIME>20091222163041
ACCESSION NUMBER:		0000950123-09-072718
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20091217
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20091222
DATE AS OF CHANGE:		20091222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		091255516

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y02773e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of<BR>
the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of Earliest Event Reported): December&nbsp;22, 2009 (December&nbsp;17, 2009)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Protalix BioTherapeutics, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in its charter)</B></DIV>


<DIV align="center" style="font-size: 10pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Florida<BR>
(State or other jurisdiction <BR>
of incorporation)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-33357<BR>
(Commission File Number)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>65-0643773<BR>
(IRS Employer<BR>
Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>2 Snunit Street <BR>
Science Park, POB 455<BR>
Carmiel, Israel<BR>
(Address of principal executive offices)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>20100<BR>
(Zip Code)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Registrant&#146;s telephone number, including area code &#043;972-4-988-9488</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>(Former name or former address, if changed since last report.)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;1.01. Entry into a Material Definitive Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;17, 2009, Protalix BioTherapeutics, Inc. (the &#147;Company&#148;), entered into an
employment agreement with Sandra L. Lauterbach (the &#147;Employment Agreement&#148;), pursuant to which Ms.
Lauterbach will serve as the Company&#146;s Vice President, Sales and Commercial Affairs. A description
of the Employment Agreement is contained in Item&nbsp;5.02 below, which is incorporated by reference
into this Item&nbsp;1.01.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company appointed Ms.&nbsp;Lauterbach to serve as its Vice President, Sales and Commercial
Affairs, effective December&nbsp;18, 2009. Pursuant to the Employment Agreement, Ms.&nbsp;Lauterbach&#146;s
annual base salary is $180,000 and the Company may elect to pay her an annual discretionary bonus
in an amount and based upon criteria determined by either the Compensation Committee of the
Company&#146;s Board of Directors (the &#147;Board&#148;), or the entire Board, at their sole discretion. She is
also entitled to certain health care insurance benefits and contributions to retirement plans, and
allowances for car and cell phone expenses. In connection with the Employment Agreement, the
Company recommended to the Board&#146;s Compensation Committee that Ms.&nbsp;Lauterbach be granted a stock option to purchase 160,000 shares of the Company&#146;s common
stock (&#147;Option&#148;) at an exercise price equal to not less than the market price of the common stock
on the date of grant. The Company further recommended that the Option vest over a period of four
years, with 25% of the Option vesting upon the lapse of one year from the date of grant (the
&#147;Initial Vesting Date&#148;) and the remainder of the Option vesting on a quarterly basis in 12 equal
installments, commencing on the Initial Vesting Date. The unvested portion of the Option will vest
automatically upon a change of control of the Company. The Employment Agreement is terminable by
either party on 60&nbsp;days&#146; written notice for any reason and the Company may terminate the Employment
Agreement for cause without notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to joining the Company, Ms.&nbsp;Lauterbach, 40, was the Vice President of Marketing,
Endocrinology of EMD Serono, Inc., from July&nbsp;2008 through July&nbsp;2009. Prior to that, from August
2003 through July&nbsp;2008, she served in a number of positions at Genzyme Corporation, the last
position being the Senior Director, Global Marketing for Fabrazyme. Ms.&nbsp;Lauterbach holds a B.Sc.
in Molecular Biology from the University of Wisconsin and an MBA from the University of South
Florida.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01. Other Events</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On December&nbsp;17, 2009, the Company issued a press release announcing the hiring of Ms.&nbsp;Lauterbach.
A copy of the press release is attached hereto as Exhibit&nbsp;99.1.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>(d)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Exhibits</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Employment Agreement by and between Protalix BioTherapeutics, Inc., and Sandra Lauterbach
dated as of December&nbsp;17, 2009.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">99.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Press release dated December&nbsp;17, 2009.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: December 22, 2009&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ David Aviezer
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">David Aviezer, Ph.D.&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">President and<br>
Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>y02773exv10w1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;10.1
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EMPLOYMENT AGREEMENT</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This EMPLOYMENT AGREEMENT (this &#147;<B>Agreement</B>&#148;) dated as of December&nbsp;17, 2009, by and between
Protalix BioTherapeutics, Inc., a Florida corporation (the &#147;<B>Company</B>&#148;), and Sandra Lauterbach (the
&#147;<B>Executive</B>&#148;) (each of the Company and Executive shall be referred to herein, as a &#147;<B>Party</B>&#148; and
collectively, the &#147;<B>Parties</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, the Company is engaged, inter alia, in the research and development of proteins and
expression thereof in plant cells cultures; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, the Company desires to employ the Executive in the position of Company&#146;s Vice
President, Sales and Commercial Affairs and the Executive desires to be employed by the Company in
such position, on the terms and conditions hereinafter set forth;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE</B>, based on the representations contained herein and in consideration of the
mutual promises and covenants set forth herein, the Parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Executive&#146;s Duties and Obligations</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Employment Term</U>. The employment of the Executive by the Company shall commence on
December&nbsp;18, 2009 (the &#147;<B>Effective Date</B>&#148;) and continue until the employment is terminated in
accordance with Section&nbsp;5 (the &#147;<B>Term</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Duties</U>. The Executive shall serve as the Company&#146;s Vice President, Sales and
Commercial Affairs. The Executive shall at all times report directly to the Company&#146;s Chief
Executive Officer (&#147;<B>CEO</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Location of Employment</U>. The Executive&#146;s principal place of business shall be in
Boston, Massachusetts; <U>provided</U>, that the Executive agrees and acknowledges that the
performance by the Executive of her duties shall require frequent travel including, without
limitation, overseas travel from time to time. Notwithstanding the foregoing, the Executive agrees
and acknowledges that the principal location of her employment by the Company may require
relocation at the Company&#146;s sole discretion. If the Company, in its sole discretion, elects to
transfer the principal location of the Executive&#146;s employment, the Company shall reimburse the
Executive for the relocation costs incurred in connection with the relocation to the extent
customarily provided to a vice president of a pharmaceutical company of the Company&#146;s size. The
Company agrees and acknowledges that such costs will include: (i)&nbsp;customary and reasonable closing
costs and realtor fees for the sale of the Executive&#146;s home at the time of relocation; (ii)&nbsp;costs
relating to the packing, transporting, storage, and unpacking of household goods; (iii)&nbsp;customary
and reasonable closing costs in connection with the Executive&#146;s purchase of a new residence in
reasonable proximity to the new principal place of business; and (iv)&nbsp;interim housing if necessary
(in case the Executive&#146;s current home does not sell in a timely manner); provided, that in no event
shall the Company be obligated to reimburse the Executive for, or pay, in excess of $50,000 under
this Section&nbsp;1(b). The Executive agrees to use commercially reasonable efforts to cause the
relocation to take place within a reasonable amount of time after the Company elects to transfer
the principal location of the Executive&#146;s
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">employment. Notwithstanding anything in this Agreement to the contrary, if it shall be
determined that the relocation costs would be subject to any income tax, then the Executive shall
be entitled to receive an additional payment in an amount such that after payment by the Executive
of all income taxes imposed upon such additional payment, the Executive retains an amount of the
additional payment equal to the income tax imposed upon the relocation costs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Company Policies</U>. The Executive agrees and acknowledges that she has been
provided with a copy of the policies adopted by the Company titled: &#147;Code of Business Conduct and
Ethics,&#148; &#147;Insider Trading Policy&#148; and &#147;Pre-clearance and Blackout Policy&#148; and undertakes to comply
and perform her duties and obligations under this Agreement in accordance with the provision of
such policies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Devotion of Time to Company&#146;s Business</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Full-Time Efforts</U>. The Executive shall be employed on a full-time basis. The
Executive shall devote her full and undivided attention and full working time to the business and
affairs of the Company and the fulfillment of her duties and responsibilities under this Agreement.
During the Term, the Executive shall not engage in any other employment nor engage in any other
business activity or render any commercial or professional services, with or without compensation,
for any other person or entity. The Executive shall notify the Company immediately of any event or
circumstance which may hinder the performance of her obligations hereunder or result in the
Executive having a conflict of interest with her position with the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Duties and Obligations</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Executive&#146;s duties and responsibilities shall be those duties and responsibilities
customarily performed by a Vice President, Sales and Commercial Affairs of a biopharmaceutical
company, as may be determined from time to time by the CEO. These will include, inter alia, the
following:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Define, build, and lead the optimal commercial structure of the Company to enable
full potential of current and future pipeline candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Optimize the Company&#146;s commercial model by leveraging and managing external
alliances/partnerships;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Develop short and long-term strategic business plans to develop and build product
strength and ensure global market success;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Lead and direct cross-functional team members and partners (i.e. Medical,
Regulatory, Promotion, Agency, PR, Operations, etc.) in the development of strategic
and operational commercial plans;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Contribute to shaping the Company&#146;s overall clinical and development strategy by
integrating market dynamics, competitive intelligence, and input from external experts;
and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Assess business development and licensing opportunities including participation in
due diligence visits.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Compensation and Benefits</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Base Compensation</U>. During the Term, the Company shall pay to the Executive (i)
base annual compensation (&#147;<B>Base Salary</B>&#148;) of $180,000, payable in accordance with the Company&#146;s
regular payroll practices and less all required withholdings and (ii)&nbsp;additional compensation, if
any, and benefits as hereinafter set forth in this Section&nbsp;3.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Bonuses</U>. During the Term, the Executive shall be eligible to one or more bonuses,
which may be paid in either cash or equity, or a combination thereof, at the sole discretion of the
Compensation Committee of the Board, or by the Board of Directors, after consultation with the CEO;
<U>provided</U>, that the Company shall be under no obligation whatsoever to pay a discretionary
bonus at any time during the Term. Such bonuses may be time-based, milestone-based or based upon
any other criteria set by the Compensation Committee of the Board, or by the Board of Directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Benefits</U>. During the Term, the Executive shall be entitled to participate in all
employee benefit plans, programs and arrangements made available generally to the Company&#146;s senior
executives or to its employees in the United States on substantially the same basis that such
benefits are provided to such executives or employees (including, without limitation
profit-sharing, savings and other retirement plans (e.g., a 401(k) plan) or programs, medical,
dental, hospitalization, vision, short-term and long-term disability and life insurance plans or
programs, accidental death and dismemberment protection, travel accident insurance, and any other
employee welfare benefit plans or programs that may be sponsored by the Company from time to time,
including any plans or programs that supplement the above-listed types of plans or programs,
whether funded or unfunded); <U>provided</U>, <U>however</U>, that nothing in this Agreement
shall be construed to require the Company to establish or maintain any such plans, programs or
arrangements. Notwithstanding anything herein to the contrary, during the Term, the Executive
shall be entitled to receive (i) $750 per month to pay for the costs incurred by the Executive to
maintain personal health insurance (&#147;<B>Health Care Costs</B>&#148;) and (ii)&nbsp;up to $540 per month in lieu of a
matching contribution by the Company to a 401(k) plan (the &#147;<B>401(k) Allocation</B>&#148;). The Executive
acknowledges and agrees that the Health Care Costs and the 401(k) Allocation shall cease to be
payable immediately upon the Company&#146;s adoption of a health care insurance plan and a 401(k) plan
that are available to the Executive. The Executive further agrees and acknowledges that the 401(k)
Allocation shall only be payable by the Company if and to the extent the Executive deposits the
same amount in a self-funded retirement plan and shall not exceed an amount equal to 50% of the
Executive&#146;s deposit of up to 6% of the Executive&#146;s Base Salary (or 3% of the Executive&#146;s Base
Salary). The Company agrees to use commercially reasonable efforts to adopt a health care
insurance plan for its employees within one year of the Effective Date. Notwithstanding anything
in this Agreement to the contrary, if it shall be determined that the Health Care Costs would be
subject to any income tax, then the Executive shall be entitled to receive an additional payment in
an amount such that after payment by the Executive of all income taxes imposed upon such additional
payment, the Executive retains an amount of the additional payment equal to the income tax imposed
upon the Health Care Costs. The Health Care Costs and the 401(k) Allocation shall be payable on a
pro rata basis for periods of less than one year.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Car Allowance</U>. The Executive shall be entitled to a car allowance equal to
$30,000 per year; <U>provided</U>, that such allowance shall be paid in accordance with the
Company&#146;s regular payroll practices and less all required withholdings; <U>provided</U>,
<U>further</U>, that the allowance shall be payable on a pro rata basis for periods of less than
one year.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Cell Phone</U>. The Executive shall be entitled to a cell phone provided by the
Company; <U>provided</U>, that allowance the Company shall not be required to pay more than $1,250
per month.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Options</U>. The Company shall recommend to the Compensation Committee and the Audit
Committee of its Board of Directors that the Executive be granted a stock option (the &#147;<B>Option</B>&#148;) to
purchase 160,000 shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;<B>Common
Stock</B>&#148;). The Option shall be granted under the Company&#146;s 2006 Stock Incentive Plan (the &#147;<B>Plan</B>&#148;).
Such recommendation shall include that the Option be subject to the following additional terms and
conditions: (i)&nbsp;vesting over a period of four years as follows: 25% of the Option shall vest upon
the lapse of one year from the date of grant of the Option (the &#147;<B>Initial Vesting Date</B>&#148;) and the
remainder of the Option shall vest on a quarterly basis in 12 equal installments, commencing on the
Initial Vesting Date; (ii)&nbsp;a purchase price per Share to be determined by the administrator of the
Plan in accordance with applicable laws and regulations and shall be not less than the market price
of the Common Stock as of the date of grant; (iii)&nbsp;the Executive must execute the standard option
agreement required under the Plan; and (iv)&nbsp;all of the outstanding Options shall vest automatically
upon a Change of Control (as defined in the Plan).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Vacations</U>. During the Term, the Executive shall be entitled to 20&nbsp;days paid
vacation per year, to be earned ratably throughout the year, five days of which may be carried over
from year to year; <U>provided</U>, that in no event shall the aggregate number of such vacation
days carried over to any succeeding year exceed 10&nbsp;days. The Executive shall coordinate her
vacation days in advance with the CEO. Paid holidays shall include the following holidays in the
United States: New Year&#146;s Day, President&#146;s Day, Memorial Day, Independence Day, Labor Day,
Thanksgiving Day and the Friday immediately following Thanksgiving Day, Christmas Eve, Christmas
Day, New Year&#146;s Eve.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Sick Leave</U>. The Executive shall be entitled to 10&nbsp;days of fully-paid sick leave
per year (pro rated for periods of less than one year).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Reimbursement of Business Expenses</U>. The Executive shall be entitled to full
reimbursement from the Company for reasonable expenses incurred in connection with the performance
of her duties hereunder, but not including travel and travel-related expenses, up to a limit of
$2,000 per month, upon submission of substantiating documents, in accordance with the Company&#146;s
policies. The Executive shall be entitled to full reimbursement from the Company for reasonable
expenses incurred in connection with travel and travel-related expenses in connection with the
performance of her duties hereunder, upon submission of substantiating documents, in accordance
with the Company&#146;s policies. The reimbursement of any expenses in excess of the foregoing limit
shall require the prior approval of the CEO.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Non-Competition and Non-Solicitation</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Non-Competition During and After Employment</U>. During the Term and for 12&nbsp;months
following the applicable date of termination (the &#147;<B>Restricted Period</B>&#148;), the Executive shall not,
directly or indirectly, without the prior written consent of the Company, either as an employee,
employer, consultant, contractor, agent, principal, partner, stockholder, corporate officer,
director, or in any other individual or representative capacity (X)&nbsp;compete with the Company in the
business of developing or commercializing recombinant therapeutic proteins or any other category of
compounds which forms the basis of the Company&#146;s material products under development or marketed
products as of the applicable date of termination or (Y)&nbsp;hire, solicit, encourage, induce or
endeavor to entice away from the Company, or otherwise interfere with the relationship of the
Company with, any person who is employed or engaged by the Company as an employee, agent,
consultant or independent contractor or who was so employed or engaged at any time during the six
months preceding the applicable date of termination.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Non Solicitation of Business</U>. The Executive agrees that during the Restricted
Period, she will not directly solicit any business which is similar to the Company&#146;s business from
individuals or entities that are customers, suppliers or contractors of the Company or any of its
subsidiaries or affiliates without the prior written consent of the CEO.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Reformation</U>. To the extent that the restrictions imposed by this Section&nbsp;4 are
interpreted by any court to be unreasonable in geographic and/or temporal scope, such restrictions
shall be deemed automatically reduced to the extent necessary to coincide with the maximum
geographic and/or temporal restrictions deemed by such court not to be unreasonable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Termination of Employment</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;This Agreement shall be in effect commencing as of the Effective Date and shall continue
in full force and effect for an undefined period, unless and until terminated by either Party upon
60&nbsp;days&#146; prior written notice to the other Party. Each of such prior notice periods shall be
referred to as the &#147;<B>Notice Period</B>,&#148; as applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Notwithstanding anything herein to the contrary, the first month of employment hereunder
shall be a trial period and therefore this Agreement may be terminated by either party effective
immediately and without need for prior written notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Notwithstanding anything herein to the contrary, the Company may terminate this Agreement
in the event of the inability of the Executive to perform her duties hereunder, whether by reason
of injury (mental or physical), illness or otherwise, incapacitating the Executive for a period
exceeding 45 calendar days and shall terminate automatically upon the death of the Executive. The
determination of whether the Executive has been incapacitated shall be made in good faith by the
Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Notwithstanding anything herein to the contrary, the Company may terminate this Agreement
at any time, effective immediately and without need for prior written notice, and without
derogating from any other remedy to which the Company may be entitled, for Cause. For the purposes
of this Agreement, the term &#147;<B>Cause</B>&#148; shall mean: (i)&nbsp;a material breach by the Executive of this
Agreement; (ii)&nbsp;any breach by the Executive of her fiduciary duties or duties of care to the
Company and its subsidiaries and affiliates; (iii)&nbsp;the Executive&#146;s
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">dishonesty or fraud or felonious conduct; (iv)&nbsp;the Executive&#146;s embezzlement of funds of the
Company or its subsidiaries or affiliates; (v)&nbsp;any conduct by the Executive, alone or together with
others, which is materially injurious to the Company and its subsidiaries and affiliates,
financially or otherwise; (vi)&nbsp;the Executive&#146;s gross negligence or willful misconduct in the
performance of her duties and/or responsibilities hereunder or to the Company; (vii)&nbsp;the
Executive&#146;s disregard or insubordination of any lawful resolution and/or instruction of the CEO
with respect to the Executive&#146;s duties and/or responsibilities to the Company; (viii)&nbsp;the
occurrence of an event or circumstance which may result in the Executive having a conflict of
interest with respect to the Company and its subsidiaries and affiliates without the Executive
having notified the Company thereof, as provided herein; or (ix)&nbsp;any breach by the Executive of her
confidentiality undertakings to the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Prior to the end of the Term or the termination of this Agreement, the Executive shall
cooperate with the Company and assist the integration into the Company&#146;s organization of the person
or persons who will assume the Executive&#146;s responsibilities, pursuant to Company&#146;s instructions.
At the option of the Company, the Executive shall, during such period, either continue with her
duties or remain absent from the premises of the Company, subject to applicable law. At any time
during the Notice Period, the Company may elect to terminate this Agreement and the relationship
with the Executive immediately; <U>provided</U>, that the Executive shall be entitled to all
payments and other benefits due to her hereunder as she would have been entitled to receive for the
remaining period of the Notice Period.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Upon termination of the Executive&#146;s employment with the Company hereunder for any reason
whatsoever, the Company shall have no further obligation or liability towards the Executive in
connection with her employment as aforesaid. The Company may set-off any outstanding amounts due
to it by the Executive against any payment due by the Company to the Executive, subject to
applicable law. Without limiting the generality of the foregoing, if the Executive fails to comply
with her notice or other obligations hereunder or under applicable law, the Company shall be
entitled to set-off any amount to which the Executive would have been entitled during the Notice
Period, from any payment due from the Company to the Executive, all without prejudice to any other
remedy to which the Company may be entitled pursuant to this Agreement or applicable law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;The provisions of Sections&nbsp;4, 5(f), 5(g), and 6, and the applicable provisions of Section
11 and any provision of the policies specified in Section 1(c) that by its terms survives the
termination of employment shall survive the termination or expiration of this Agreement for any
reason whatsoever.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Confidentiality</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Executive hereby agrees that she shall not, directly or indirectly, disclose or use at
any time any trade secrets or other confidential information of any type or nature, whether
patentable or not, of the Company, its subsidiaries or affiliates now or hereafter existing,
including but not limited to: any (i)&nbsp;processes, formulas, trade secrets, copyrights, innovations,
inventions, discoveries, improvements, research or development and test results, specifications,
data, patents, patent applications and know-how of any type or nature; (ii)&nbsp;marketing plans,
business plans, strategies, forecasts, financial information, budgets, projections,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">product plans and pricing; (iii)&nbsp;personnel information, salary, and qualifications of
employees; (iv)&nbsp;agreements, customer and supplier information, including identities and product
sales forecasts; and (v)&nbsp;any other information of a confidential or proprietary nature
(collectively, &#147;<B>Confidential Information</B>&#148;), of which the Executive is or becomes informed or aware
during the Term or otherwise in the course of her employment by the Company, whether or not
developed by the Executive, it being agreed that for purposes of this Section&nbsp;6, the term
Confidential Information shall not include information that has entered into the public domain
through no wrongful act by Executive. Upon termination or expiration of this Agreement, or at any
other time upon request of the Company, the Executive shall promptly deliver to the Company all
physical and electronic copies and other embodiments of Confidential Information and all memoranda,
notes, notebooks, records, reports, manuals, drawings, blueprints and any other documents or things
belonging to the Company, and all copies thereof, in all cases, which are in the possession or
under the control of the Executive.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Executive hereby acknowledges and that all Confidential Information and any other
rights in connection therewith are and shall at all times remain the sole property of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Creations and Inventions</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company shall be the sole and exclusive owner of any Inventions (as defined below),
and Executive hereby assigns to the Company any and all of her rights, title and interest in such
intellectual property free and clear of any rights of any third party. The Executive shall inform
the Company of any Invention relating to the Company&#146;s technology, its applications components or
any intellectual property relating thereto, and shall execute any necessary assignments, patent
forms and the like and will assist in the drafting of any description or specification of the
Invention as may be required for the Company&#146;s records and in connection with any application for
patents or other forms of legal protection that may be sought by the Company. The Executive shall
treat all information relating to any Invention as Confidential Information according to Section&nbsp;6.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Without limiting the foregoing, &#147;<B>Inventions</B>&#148; shall include any and all intellectual
property, including without limitation, ideas, inventions, processes, formulas, source and object
codes, data, programs, know how, improvements, discoveries, designs, techniques, trade secrets,
patents and patents applications, copyrights, mask work and any other intellectual property rights
throughout the world, generated, produced, reduced to practice, or developed by the Executive
during or in connection with her employment by the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Company&#146;s rights under this Section&nbsp;7 shall be worldwide and shall apply to any such
Invention notwithstanding that it is perfected or reduced to specific form after the Executive has
ceased her services hereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Injunctive Relief</U>. If the Executive breaches any provisions of any of Sections&nbsp;4,
6 or 7, or there is a threatened breach thereof, then, in addition to any other rights which the
Company may have, the Company shall be entitled, without the posting of a bond or other security,
to injunctive relief to enforce the restrictions contained therein and for reimbursement for the
costs and attorney&#146;s fees incurred by the Company in enforcing its rights thereunder. The
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Executive agrees and acknowledges that her compensation under this Agreement are being paid,
for among other reasons, as consideration for the undertakings set forth in each of Sections&nbsp;4, 6
or 7. If an actual proceeding is brought in equity to enforce the provisions of any of Sections&nbsp;4,
6 or 7, the Executive shall not urge as a defense that there is an adequate remedy at law nor shall
the Company be prevented from seeking any other remedies which may be available.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Notices</U>. Any and all notices and other communications in connection with this
Agreement shall be in writing, addressed to the parties as follows:
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="6%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="right">(a)</TD>
    <TD>&nbsp;</TD>
    <TD>if to the Company:</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="6%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"></TD>
    <TD>&nbsp;</TD>
    <TD>Protalix BioTherapeutics, Inc.<br>
2 Snunit Street<br>
POB 455<br>
Carmiel 20100, Israel<br>
Attn: CEO or CFO</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="6%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="right">(b)</TD>
    <TD>&nbsp;</TD>
    <TD>if to the Executive:</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="6%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"></TD>
    <TD>&nbsp;</TD>
    <TD>Sandra Lauterbach<BR>
The address on file with the records of the Company</TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All notices shall be given by registered mail (postage prepaid), by facsimile or email or otherwise
delivered by hand or by messenger to the Parties&#146; respective addresses as above or such other
address as may be designated by notice. Any notice sent in accordance with this Section&nbsp;9 shall be
deemed received upon the earlier of: (i)&nbsp;if sent by facsimile or email, upon transmission and
electronic confirmation of transmission or, if transmitted and received on a non-business day, on
the first business day following transmission and electronic confirmation of transmission; (ii)&nbsp;if
sent by registered mail, upon three days of mailing; (iii)&nbsp;if sent by messenger, upon delivery;
(iv)&nbsp;the actual receipt thereof. Addresses may be changed by written notice sent to the other
party at the last recorded address of that party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Withholding</U>. The Company shall be entitled to withhold all federal, state or
local withholding or other taxes from payments due under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Miscellaneous</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Governing Law</U>. This Agreement shall be interpreted, construed, governed and
enforced according to the laws of the State of New York without regard to the application of choice
of law rules of such State. Any dispute arising out of or relating to this Agreement shall be
exclusively resolved in the Courts of the State of New York.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Amendments</U>. No amendment or modification of the terms or conditions of this
Agreement shall be valid unless in writing and signed by the parties hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Severability</U>. The provisions of this Agreement shall be deemed severable and the
invalidity or unenforceability of any provision shall not affect the validity or enforceability of
the other provisions hereof. If any part of this Agreement is determined to be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">invalid, illegal or unenforceable, such determination shall not affect the validity, legality
or enforceability of any other part of this Agreement; and the remaining parts shall be enforced as
if such invalid, illegal, or unenforceable part were not contained herein; <U>provided</U>,
<U>however</U>, that in such event this Agreement shall be interpreted so as to give effect, to
the greatest extent consistent with and permitted by applicable law, to the meaning and intention
of the excluded provision as determined by such court of competent jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Successors and Assigns</U>. Neither this Agreement nor any of the Executive&#146;s rights,
privileges, or obligations set forth in, arising under, or created by this Agreement may be
assigned or transferred by the Executive without the prior consent in writing of the Company. The
Company shall be entitled to assign its rights and obligations hereunder to any entity acquiring a
material part of its assets or to a subsidiary, affiliate or parent company thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Remedies Cumulative; No Waiver</U>. No remedy conferred upon either party by this
Agreement is intended to be exclusive of any other remedy, and each and every such remedy shall be
cumulative and shall be in addition to any other remedy given hereunder or now or hereafter
existing at law or in equity. No delay or omission by either party in exercising any right, remedy
or power hereunder or existing at law or in equity shall be construed as a waiver thereof, and any
such right, remedy or power may be exercised by such party from time to time and as often as may be
deemed expedient or necessary by such party in such party&#146;s sole discretion.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Waivers</U>. The observance of any term of this Agreement may be waived (either
prospectively or retroactively and either generally or in a particular instance) only with the
written consent of the Party against which/whom such waiver is sought. No waiver by either Party
at any time to act with respect to any breach or default by the other Party of, or compliance with,
any condition or provision of this Agreement to be performed by such other Party shall be deemed a
waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent
time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the
Parties with respect to the subject matters hereof and cancels and supersedes all prior agreements,
understandings and arrangements, oral or written, between the Parties with respect to such subject
matters.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of
which shall constitute an original, but all of which, when taken together, shall constitute one
document.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Headings; Interpretation</U>. Section and Subsection headings contained herein are
for reference and convenience purposes only and shall not in any way be used for the interpretation
of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>No Contract of Employment</U>. Nothing contained in this Agreement will be construed
as a right of the Executive to be continued in the employment of the Company, or as a limitation of
the right of the Company to discharge the Executive with or without Cause.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Executive Acknowledgement</U>. The Executive hereby acknowledges that she has read
and understands the provisions of this Agreement, that she has been given the opportunity for her
legal counsel to review this Agreement, that the provisions of this Agreement are reasonable and
that she has received a copy of this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have caused this Employment Agreement to be executed as
of the date first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ David Aviezer
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">David Aviezer, Ph.D&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">CEO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">               /s/ Sandra Lauterbach
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Sandra Lauterbach&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>y02773exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;99.1
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">CARMIEL, Israel, December&nbsp;17, 2009 &#151; Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) today
announced the appointment of Sandra Lauterbach to Vice President, Sales and Commercial Affairs. In
this newly created, U.S. based position, Ms.&nbsp;Lauterbach will be responsible for all commercial
activities, including pre-launch and launch activities for taliglucerase alfa in accordance with
the collaboration agreement between the Company and Pfizer Inc., as well as any other products that
emerge from the Company&#146;s pipeline. Ms.&nbsp;Lauterbach brings over 20&nbsp;years of expertise in U.S. and
global marketing, commercial strategy, and product development for pharmaceutical and biotechnology
companies. Prior to joining the Company, she served as Vice President of Marketing, Endocrinology
at EMD Serono and Senior Director, Global Marketing for Fabrazyme at Genzyme Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are delighted to have someone with Sandra&#146;s sales and commercial experience join Protalix,&#148;
said Dr.&nbsp;David Aviezer, the Company&#146;s President and Chief Executive Officer. &#147;Her experience and
track record with pre-launch and launch activities, particularly in the rare genetic disease space,
will be a tremendous asset to our company as we transition from a research and development
organization to a fully integrated biotechnology company.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ms.&nbsp;Lauterbach&#146;s career includes more than 20&nbsp;years of sales and marketing experience in the
healthcare industry. As Vice President of Marketing, Endocrinology at EMD Serono, she developed,
executed, and managed the national marketing strategies for Saizen<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, Gonal-f<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and Serostim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. Prior
to her tenure at Serono, Ms.&nbsp;Lauterbach spent four years at Genzyme leading the international
product team for Fabrazyme, which produced double-digit annual growth for three straight years.
Her background also includes several years with Immune Mediated Disease, Vertex Pharmaceuticals
Incorporated, Amgen Inc. and Merck Human Health.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ms.&nbsp;Lauterbach received her Bachelor of Science in Molecular Biology from the University of
Wisconsin and her Masters in Business Administration from the University of South Florida.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Protalix</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Protalix is a biopharmaceutical company focused on the development and commercialization of
proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based
expression system. Protalix&#146;s ProCellEx&#153; presents a proprietary method for the expression of
recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale
production of recombinant therapeutic proteins in an environment free of mammalian components and
viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development
programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special
Protocol Assessment with the U.S. Food and Drug Administration for Gaucher disease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Safe Harbor Statement:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To the extent that statements in this press release are not strictly historical, all such
statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known
and unknown risks and
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">uncertainties that may cause actual future experience and results to differ materially from the
statements made. These statements are based on our current beliefs and expectations as to such
future outcomes. Drug discovery and development involve a high degree of risk. Factors that might
cause material differences include, among others, risks relating to: the successful preclinical
development of our product candidates; the completion of clinical trials; the review process of the
FDA, foreign regulatory bodies and other governmental regulatory bodies, including the FDA&#146;s review
of any filings we make in connection with the treatment protocol; delays in the FDA&#146;s or other
health regulatory authorities&#146; approval of any applications we file or refusals to approve such
filings; refusals by such regulatory authorities to approve the marketing and sale of a drug
product even after acceptance of an application we file for any such drug product; the
identification of lead compounds; the risk that we may fail to satisfy certain conditions relating
to grants we have received from the Office of the Chief Scientist of Israel&#146;s Ministry of Industry
and Trade which may lead to our being required to refund grants previously received together with
interest and penalties; the risk that the Office of the Chief Scientist may not deliver to us all
of the funds awarded to us; uncertainties related to the ability to attract and retain partners for
our technologies and products under development; and other factors described in our filings with
the Securities and Exchange Commission. Companies in the pharmaceutical and biotechnology
industries have suffered significant setbacks in advanced or late-stage clinical trials, even after
obtaining promising earlier trial results or in preliminary findings for such clinical trials.
Further, even if favorable testing data is generated by clinical trials of drug products, the FDA
may not accept or approve an NDA filed by a pharmaceutical or biotechnology company for such drug
product. Failure to obtain FDA approval of any of our drug candidates in a timely manner, if at
all, will severely undermine our business and results of operation by reducing our potential
marketable products and our ability to generate corresponding product revenues. Under our approved
treatment protocol, taliglucerase alfa might be provided only to a limited number of patients and
only for a limited time. The FDA&#146;s approval of the treatment protocol or the fast track
designation will not have any effect on the FDA&#146;s approval of the NDA we filed with respect to
taliglucerase alfa, if any, and the review by the FDA of any data from our Phase III clinical
development programs in connection with the approval of the treatment protocol will not have any
effect on the FDA&#146;s subsequent review of our complete Phase III clinical trial data in the future.
The statements in this release are valid only as of the date hereof and we disclaim any obligation
to update this information.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Contact:</B><BR>
Marcy Nanus<BR>
The Trout Group, LLC<BR>
Telephone: 646-378-2927<BR>
Email: <U>mnanus@troutgroup.com</u>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Media Contact:</B><BR>
Brad Miles<BR>
BMC Communications Group, LLC<BR>
Telephone: 212-477-9007 x17<BR>
Email: brad@bmccommunications.com

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
